Dermatology
Skin clinical trials
Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We’re tracking 5,025 recruiting studies in this area right now.
By phase
- Not applicable2,810
- Phase 2752
- Phase 1523
- Phase 3382
- Phase 1/Phase 2296
- Phase 4203
- Phase 2/Phase 359
Top conditions
- Breast Cancer1,192
- Melanoma174
- Metastatic Breast Cancer138
- Rheumatoid Arthritis131
- Atopic Dermatitis124
- Systemic Lupus Erythematosus119
- Breast Neoplasms111
- Triple Negative Breast Cancer110
- Colorectal Cancer94
- Ovarian Cancer91
- Psoriasis85
- Breast Carcinoma79
- Lung Cancer77
- Prostate Cancer70
- Rheumatoid Arthritis (RA)68
- Diabetic Foot Ulcer59
- Cancer58
- Systemic Lupus Erythematosus (SLE)52
Leading sponsors
- Fudan University64
- M.D. Anderson Cancer Center51
- Novartis Pharmaceuticals49
- Memorial Sloan Kettering Cancer Center48
- Mayo Clinic40
- AstraZeneca38
- Assistance Publique - Hôpitaux de Paris37
- National Cancer Institute (NCI)37
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University34
- Second Affiliated Hospital, Zhejiang University, School of Medicine30
Where studies are running
- California408
- Arizona150
- Alabama129
- Florida126
- New York110
- Texas106
- Maryland94
- Massachusetts87
- Pennsylvania72
- North Carolina68
Recruiting studies5,025 total
- NCT06073171Recruiting
Genes and skin pattern study for cutis tricolor
This study looks at the genes of people with cutis tricolor, a rare skin condition with three colors, to understand what causes it. You and your parents (one affected, one not) can help by donating a blood sample for DNA analysis.
MontpellierAges 4–60 - NCT06201416RecruitingPhase 1
Single dose of SBT777101 for rheumatoid arthritis
This study tests a single dose of an experimental drug called SBT777101 for people with moderate to severe rheumatoid arthritis who have already tried and failed at least two advanced treatments. The goal is to see if it is safe and how the body handles it.
Scottsdale, ArizonaAges 18–70 - NCT06189157RecruitingPhase 1/Phase 2
Testing MB-CART19.1 therapy for severe lupus
This trial tests a new type of treatment called CAR T-cell therapy (MB-CART19.1) for people with severe lupus that has not responded to other treatments. It aims to see if this therapy can help control lupus and improve organ function.
ErlangenAges 18 years+ - NCT06189209RecruitingPhase 2
Tenalisib for metastatic triple-negative breast cancer
This trial tests a drug called Tenalisib in people with metastatic triple-negative breast cancer who have already tried 1 to 3 chemotherapy treatments. It aims to see if Tenalisib can help shrink tumors and improve outcomes.
Vijayawada, Andhra PradeshAges 18 years+ - NCT06192563Recruiting
Dupilumab for severe eczema with limited skin rash
This study looks at how well dupilumab works for children and teens with severe eczema (atopic dermatitis) even when the rash is not widespread. It aims to see if the treatment helps with itching, quality of life, and rashes in visible or sensitive areas.
BolognaAges 6 months–17 years - NCT06195072RecruitingPhase 2
Platform study for scleroderma with lung disease
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
Birmingham, AlabamaAges 18 years+ - NCT06194929RecruitingPhase 1/Phase 2
Drug combo for melanoma that spread to the brain
This trial tests a combination of two or three drugs (defactinib, avutometinib, with or without encorafenib) to shrink brain tumors that started from skin melanoma. It may be an option for people whose melanoma has a specific genetic change and who have already tried immunotherapy.
Iowa City, IowaAges 18 years+ - NCT06193369Recruiting
Digital peer support for young adults with cancer
This trial connects you with a trained peer (someone who has been through cancer) who provides support and guidance online. It's for young adults who finished treatment for certain cancers in the past year.
Toronto, OntarioAges 18–40 - NCT06182293Recruiting
Mouth bacteria in early systemic sclerosis
This study looks at the bacteria in the mouth (periodontal microbiota) of people with early systemic sclerosis compared to those without the condition. It may help understand if there is a link between oral health and systemic sclerosis.
StrasbourgAges 18 years+ - NCT06195709RecruitingPhase 3
Study of PET imaging and blood tests for ER+ HER2- metastatic breast cancer
This trial tests a new imaging technique (18F-FES PET/CT) along with blood markers to guide treatment for metastatic breast cancer that is ER-positive and HER2-negative. It's for people whose cancer progressed on first-line hormone therapy and who are starting a second line of hormone therapy.
BayonneAges 18 years+ - NCT06199713Recruiting
Melanoma trial tracking treatment response with PET scans and blood tests
This study is looking at whether a special PET scan (FDG PET/CT) and a blood test that measures ctDNA (cancer DNA in the blood) can help predict how well immune checkpoint inhibitors work in people with advanced melanoma. If you are planning to get treatment with immunotherapy drugs like ipilimumab, nivolumab, or pembrolizumab, you may be able to join.
Madison, WisconsinAges 18 years+ - NCT06185205RecruitingPhase 2
Accelerated high-dose radiation for early breast cancer
This trial tests a very short, high-dose radiation treatment given directly to the breast after lumpectomy. It aims to make radiation more convenient by finishing in just a few days instead of weeks, possibly with fewer side effects.
Richmond, VirginiaAges 45–79 - NCT06201234RecruitingPhase 2
Adding elacestrant to olaparib for advanced HR+/HER2- breast cancer
This trial tests if adding a new oral medicine (elacestrant) to a standard PARP inhibitor (olaparib) works better for people with advanced or metastatic HR+/HER2- breast cancer who have a BRCA1 or BRCA2 gene mutation. The goal is to see if the combination can help control the cancer longer.
Stuttgart, Baden-WurttembergAges 18 years+ - NCT02143986Recruiting
Testing glycosylated ferritin to evaluate inflammation
This trial looks at a blood test called “glycosylated ferritin” to help doctors better identify certain dangerous inflammatory conditions. It may help clarify whether your high iron-related marker is due to inflammation rather than other causes.
BrusselsAges Up to 85 years - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Duarte, CaliforniaAges 18 years+ - NCT06171750RecruitingPhase 1
Study of ANK-101 for advanced solid tumors
This trial tests a new drug, ANK-101, injected directly into tumors to help fight advanced solid tumors that have spread or can't be treated with standard therapies. It may be an option if you have a tumor that can be reached for injection.
Bethesda, MarylandAges 18 years+ - NCT06167694RecruitingPhase 1/Phase 2
Study of HRS-8080 and Dalpiciclib for advanced breast cancer
This trial tests a new combination of two drugs (HRS-8080 and Dalpiciclib) for women with advanced breast cancer that cannot be removed by surgery. It may be an option if you have already tried hormone therapy or are starting advanced treatment for the first time.
Beijing, Beijing MunicipalityAges 18–75 - NCT06158490Enrolling by invitationPhase 2
JYP0061 tablet for moderate to severe eczema
This trial tests a new tablet called JYP0061 for people with moderate to severe atopic dermatitis (eczema) that has lasted at least a year. It aims to see if the drug is safe and effective in reducing symptoms.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06171607RecruitingPhase 1
Ultrasound with contrast to help spot breast lumps
This trial uses a special ultrasound with a contrast agent to get clearer images of breast lumps. It may help doctors decide if a lump needs a biopsy.
Los Angeles, CaliforniaAges 18 years+ - NCT06177106Recruiting
Study of skin markers in sun-damaged and protected skin
This trial looks at certain markers in the skin of people with sun damage. It tests how your skin reacts to a small amount of simulated sunlight, and may help understand skin cancer risk.
Tucson, ArizonaAges 40 years+ - NCT06169371RecruitingPhase 4
Abemaciclib dose escalation for early breast cancer
This study tests whether women with early-stage HR+/HER2- breast cancer can safely take a higher dose of the drug abemaciclib (Verzenio) after surgery. The goal is to keep the treatment as strong as possible while managing side effects.
Chicago, IllinoisAges 18 years+ - NCT06176261RecruitingPhase 2
Datopotamab deruxtecan for breast cancer with brain spread
This trial tests a new drug called datopotamab deruxtecan for people with HER2-negative breast cancer that has spread to the brain. It looks at how well the drug works against brain metastases.
Miami, FloridaAges 18 years+ - NCT06159166RecruitingPhase 1/Phase 2
Mirdametinib for NF1 skin bumps
This study tests an oral drug called mirdametinib to see if it can shrink skin bumps caused by NF1. If you have at least 24 of these bumps on your skin and are in decent health, you may be able to join.
Baltimore, MarylandAges 18 years+ - NCT06178289Enrolling by invitation
Skin protectant for moisture damage in hospitals
This trial tests a new skin protectant lotion for people in the hospital with skin damage from moisture (like urine or stool). It aims to see if the lotion helps heal these wounds better than current care.
AntwerpAges 18 years+
Common questions
- How many skin clinical trials are recruiting?
- Clin2 is tracking 5,025 recruiting dermatology studies from the U.S. registry right now, out of 7,809 we cover in this area in total.
- What does “Skin” cover here?
- Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We group each study into skin based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a skin trial near me?
- Use the search to filter skin studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.